Videos

CancerNetwork® sat down with Stephen V. Liu, MD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about pralsetinib for patients with non–small cell lung cancer harboring RET fusions and adequate biomarker testing in the frontline.

CancerNetwork® sat down with Alison Schram, MD, to discuss her thoughts on research with the greatest potential to positively influence patient care being presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Key opinion leaders discuss recent advancements and future directions in the HER2+ breast cancer space.

Expert panelists react to polling questions and give their input on the management both symptomatic and asymptomatic interstitial lung disease in HER2+ breast cancer, also touching on this impact in the era of COVID-19.

Experts discuss the careful monitoring of potential interstitial lung disease symptoms, how they proceed if symptoms progress, and how they handle this in patients who are asymptomatic.

During an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.

CancerNetwork® sat down with Health and Wellness expert Sonia Jhas to discuss best practices for staying active on a busy, demanding schedule.

CancerNetwork® spoke with Albert H. Kim, MD, PhD, about a new Brain Tumor Center at Siteman, for which he is the inaugural director.

Sameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.

Implications for using the Oncotype DX Breast Recurrence Score to help tailor therapy for patients with HR-positive, HER2-negative breast cancer based on data demonstrated in the TAILORx and RxPONDER studies.

A key opinion leader reviews the role of PI3K kinase inhibitors in the third-line or later settings for the treatment of follicular lymphoma.

A discussion on the types of information provided by genetic tests and genomic assays and recommendations for use in HR-positive breast cancer.

The value of utilizing a genomic test to help guide decisions for adjuvant therapy for HR-positive breast cancer.

A discussion regarding typical response rates to frontline therapy for extensive-stage small cell lung cancer and considerations for incorporating an immunotherapy agent into first-line treatment.

An overview of current gaps in treatment for patients with extensive-stage, or metastatic small cell lung cancer.

Experts in breast cancer respond to polling questions surrounding the recognition of pneumonitis and interstitial lung disease.

A panel of experts weighs in the challenges of optimally sequencing therapy for patients with HER2+ breast cancer.

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the exemestane/leuprolide acetate plus pembrolizumab combination.

Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.

Dr Kevin Kalinsky describes when and for whom neoadjuvant therapy may be appropriate for the management of HR-positive breast cancer.

Debu Tripathy, MD, of the University of Texas MD Anderson Cancer Center, comments on current NCCN recommendations for the use of prognostic and predictive gene profiling assays to individualize treatment in patients with HR-positive breast cancer.

Dr Benjamin Levy describes common treatment approaches for patients with limited-stage small cell lung cancer and extensive-stage small cell lung cancer.

Considerations for using gene profiling assays to identify appropriate patients for neoadjuvant therapy in early-stage HR-positive breast cancer.

A leader in diagnosis and management of CRC reviews the role of MRD testing in early stage CRC.

Benjamin Levy, MD, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, comments on risk factors and the prognosis for patients diagnosed with small cell lung cancer.

Results of 2 prospective, randomized clinical trials of the Oncotype DX Breast Recurrence Score and implications for practice.

Practical implications of the IMpower133 study for providers and patients.

The role of gene profiling assays in identifying candidates for chemotherapy in early HR-positive breast cancer.

Dr Mark Socinski reviews the IMpower133 trial of first-line chemotherapy plus atezolizumab in extensive-stage small cell lung cancer.